University of Ferrara

Running trials

• Recruiting

  ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

  NCT07342478· Phase 3· Newave Pharmaceutical Inc· Source

• Recruiting

  Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable

  NCT07430956· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

  NCT07363694· Phase 2/3· Pfizer· Source

• Not yet recruiting

  Arthritis interception with Guselkumab in subclinical psoriatic arthritis patients in clinical transition from skin to joint disease: a randomized clinical trial.

  2025-523551-54-00· Phase 4· Azienda Sanitaria Universitaria Friuli Centrale· Source

• Recruiting

  Impact of Mediterranean Diet and Processed Food Consumption on Gastrointestinal Symptoms in Coeliac Patients on a Gluten-Free Diet

  NCT07915063· Istituti Clinici Scientifici Maugeri SpA· Source

• Active, not recruiting

  Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)

  NCT06155279· Phase 2· Istituto Oncologico Veneto IRCCS· Source

• Active, not recruiting

  A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

  NCT06411249· Phase 4· GlaxoSmithKline· Source

• Active, not recruiting

  A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

  NCT05963074· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

  NCT06079879· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

  NCT05889182· Phase 3· AbbVie· Source

• Active, not recruiting

  HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.

  NCT05636176· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

  NCT05624749· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

  NCT05654623· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

  NCT05306340· Phase 3· Genentech, Inc.· Source

• Recruiting

  Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients

  NCT05491200· Phase 4· Research Maatschap Cardiologen Rotterdam Zuid· Source

• Active, not recruiting

  A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

  NCT05132582· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

  NCT04963296· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Pullback Pressure Gradient (PPG) Global Registry

  NCT04789317· VZW Cardiovascular Research Center Aalst· Source

• Recruiting

  Complete Mesocolic Excision in Comparison With Conventional Surgery for the Right Colon Cancer

  NCT04871399· University of Turin, Italy· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic lymphocytic leukaemia2 recruiting
• Atrial fibrillation1 recruiting
• Coeliac disease1 recruiting
• Colorectal cancer1 recruiting
• COPD1 recruiting
• Coronary artery disease1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Psoriatic arthritis1 recruiting
• Stroke1 recruiting

Closed trials

• Completed

  A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa

  2024-511360-87-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Completed

  Comprehensive Ultrasound Evaluation as a Predictor of Weaning

  NCT05539599· Università degli Studi di Ferrara· Source

• Completed

  MelaMEd Online Training for General Practitioners to Improve Melanoma Detection and Management

  NCT07757386· Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS· Source

• Completed

  Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

  NCT04930094· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Completed

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

  NCT04609878· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

  NCT04623541· Phase 1/2· Genmab· Source

• Completed

  Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

  NCT04179175· Phase 3· Novartis Pharmaceuticals· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Asthma60 works · 1 trial
• COPD31 works · 1 trial
• Deep vein thrombosis and pulmonary embolism26 works · 1 trial
• Hidradenitis suppurativa15 works · 3 trials
• Haemophilia10 works · 0 trials
• Alopecia areata7 works · 0 trials
• Peripheral artery disease6 works · 0 trials
• Mesothelioma6 works · 1 trial
• Thalassaemia6 works · 0 trials
• Coeliac disease5 works · 1 trial
• Cushing's syndrome4 works · 0 trials
• Vascular dementia4 works · 0 trials
• Vitiligo4 works · 0 trials
• Polymyalgia rheumatica3 works · 0 trials